| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 98 | 2025 | 106 | 27.870 |
Why?
|
| Anticholesteremic Agents | 78 | 2025 | 83 | 22.920 |
Why?
|
| Cholesterol, LDL | 114 | 2025 | 150 | 21.590 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 52 | 2024 | 58 | 14.080 |
Why?
|
| Cardiovascular Diseases | 45 | 2025 | 237 | 10.430 |
Why?
|
| Antibodies, Monoclonal | 32 | 2025 | 142 | 8.820 |
Why?
|
| Antibodies, Monoclonal, Humanized | 33 | 2025 | 77 | 7.890 |
Why?
|
| Atherosclerosis | 23 | 2024 | 100 | 7.490 |
Why?
|
| Homozygote | 41 | 2025 | 61 | 7.180 |
Why?
|
| Hypercholesterolemia | 25 | 2023 | 33 | 6.520 |
Why?
|
| Humans | 234 | 2025 | 14537 | 5.790 |
Why?
|
| Proprotein Convertase 9 | 39 | 2025 | 43 | 5.500 |
Why?
|
| Dyslipidemias | 18 | 2025 | 57 | 5.290 |
Why?
|
| Receptors, LDL | 26 | 2025 | 29 | 4.940 |
Why?
|
| Treatment Outcome | 55 | 2025 | 889 | 4.560 |
Why?
|
| Male | 128 | 2025 | 6754 | 4.050 |
Why?
|
| Proprotein Convertases | 12 | 2015 | 12 | 3.840 |
Why?
|
| Female | 133 | 2025 | 9103 | 3.670 |
Why?
|
| Middle Aged | 90 | 2025 | 3601 | 3.670 |
Why?
|
| Lipoprotein(a) | 12 | 2024 | 13 | 3.650 |
Why?
|
| Blood Component Removal | 10 | 2024 | 12 | 3.210 |
Why?
|
| Ezetimibe | 15 | 2024 | 15 | 3.140 |
Why?
|
| Hyperlipidemias | 10 | 2024 | 13 | 3.080 |
Why?
|
| Adult | 98 | 2025 | 5913 | 2.970 |
Why?
|
| Cholesterol | 15 | 2023 | 38 | 2.840 |
Why?
|
| RNA, Small Interfering | 14 | 2024 | 49 | 2.810 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2024 | 139 | 2.550 |
Why?
|
| Aged | 40 | 2024 | 1740 | 2.540 |
Why?
|
| Double-Blind Method | 23 | 2024 | 272 | 2.210 |
Why?
|
| Serine Endopeptidases | 12 | 2015 | 12 | 2.170 |
Why?
|
| Heterozygote | 23 | 2025 | 43 | 2.160 |
Why?
|
| Hypolipidemic Agents | 10 | 2022 | 10 | 2.150 |
Why?
|
| Oligonucleotides | 9 | 2019 | 19 | 2.140 |
Why?
|
| Adolescent | 52 | 2025 | 2985 | 2.140 |
Why?
|
| Risk Factors | 41 | 2025 | 1475 | 1.990 |
Why?
|
| Child | 38 | 2025 | 2242 | 1.910 |
Why?
|
| Angiopoietin-like Proteins | 5 | 2022 | 9 | 1.910 |
Why?
|
| Biomarkers | 28 | 2024 | 327 | 1.880 |
Why?
|
| Phenotype | 20 | 2025 | 158 | 1.790 |
Why?
|
| Young Adult | 25 | 2025 | 2498 | 1.760 |
Why?
|
| Practice Guidelines as Topic | 16 | 2019 | 127 | 1.640 |
Why?
|
| Lipid Metabolism | 7 | 2023 | 44 | 1.550 |
Why?
|
| Mutation | 22 | 2022 | 306 | 1.520 |
Why?
|
| Genetic Testing | 9 | 2023 | 34 | 1.470 |
Why?
|
| Lipids | 13 | 2022 | 81 | 1.420 |
Why?
|
| Drug Therapy, Combination | 17 | 2024 | 279 | 1.400 |
Why?
|
| Apolipoprotein B-100 | 10 | 2022 | 11 | 1.390 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2024 | 176 | 1.390 |
Why?
|
| South Africa | 50 | 2024 | 7596 | 1.370 |
Why?
|
| Benzimidazoles | 5 | 2019 | 13 | 1.370 |
Why?
|
| Hypertension | 10 | 2024 | 419 | 1.340 |
Why?
|
| Serine Proteinase Inhibitors | 5 | 2024 | 6 | 1.340 |
Why?
|
| Myocardial Infarction | 5 | 2024 | 24 | 1.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 10 | 1.260 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 10 | 1.230 |
Why?
|
| Glycated Hemoglobin A | 4 | 2017 | 24 | 1.120 |
Why?
|
| Cross-Over Studies | 4 | 2025 | 40 | 1.080 |
Why?
|
| Blood Pressure | 6 | 2021 | 317 | 1.070 |
Why?
|
| Triglycerides | 15 | 2025 | 47 | 1.060 |
Why?
|
| Apolipoproteins B | 11 | 2022 | 13 | 1.050 |
Why?
|
| Time Factors | 12 | 2024 | 507 | 0.990 |
Why?
|
| Coronary Disease | 10 | 2014 | 17 | 0.990 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2020 | 14 | 0.990 |
Why?
|
| Retrospective Studies | 11 | 2024 | 799 | 0.980 |
Why?
|
| Diabetes Mellitus | 8 | 2024 | 146 | 0.970 |
Why?
|
| Coronary Artery Disease | 8 | 2020 | 30 | 0.940 |
Why?
|
| Risk Assessment | 15 | 2023 | 225 | 0.940 |
Why?
|
| Heptanoic Acids | 6 | 2007 | 10 | 0.930 |
Why?
|
| Pyrroles | 6 | 2007 | 12 | 0.930 |
Why?
|
| Registries | 8 | 2025 | 91 | 0.920 |
Why?
|
| Down-Regulation | 8 | 2020 | 22 | 0.920 |
Why?
|
| Cholesterol, HDL | 13 | 2018 | 32 | 0.880 |
Why?
|
| Obesity | 10 | 2025 | 367 | 0.870 |
Why?
|
| Mortality, Premature | 1 | 2023 | 6 | 0.870 |
Why?
|
| Hypophosphatemia | 1 | 2023 | 2 | 0.860 |
Why?
|
| Simvastatin | 6 | 2024 | 10 | 0.860 |
Why?
|
| Cross-Sectional Studies | 14 | 2025 | 1422 | 0.850 |
Why?
|
| HIV Infections | 9 | 2024 | 5097 | 0.840 |
Why?
|
| Insulin Resistance | 11 | 2012 | 79 | 0.830 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 69 | 0.830 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 30 | 0.810 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2022 | 1 | 0.810 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2019 | 43 | 0.800 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2018 | 125 | 0.780 |
Why?
|
| Hyperlipoproteinemia Type III | 1 | 2021 | 3 | 0.760 |
Why?
|
| Life Style | 6 | 2021 | 86 | 0.760 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 12 | 0.750 |
Why?
|
| Addison Disease | 1 | 2021 | 2 | 0.750 |
Why?
|
| Hyperpigmentation | 1 | 2021 | 2 | 0.750 |
Why?
|
| Smoking | 3 | 2021 | 100 | 0.690 |
Why?
|
| RNA Interference | 1 | 2020 | 45 | 0.680 |
Why?
|
| Prevalence | 13 | 2025 | 1192 | 0.680 |
Why?
|
| Neck | 1 | 2019 | 2 | 0.680 |
Why?
|
| Salivary Gland Calculi | 1 | 2019 | 2 | 0.680 |
Why?
|
| Neck Pain | 1 | 2019 | 3 | 0.680 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2019 | 6 | 0.680 |
Why?
|
| Genetic Therapy | 1 | 2020 | 35 | 0.680 |
Why?
|
| Age Factors | 10 | 2024 | 370 | 0.660 |
Why?
|
| Genetic Variation | 2 | 2020 | 175 | 0.660 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 13 | 0.650 |
Why?
|
| Arteriosclerosis | 7 | 2000 | 24 | 0.650 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2024 | 20 | 0.620 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 5 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2000 | 22 | 0.590 |
Why?
|
| Carrier Proteins | 3 | 2019 | 23 | 0.580 |
Why?
|
| Antihypertensive Agents | 2 | 2015 | 64 | 0.570 |
Why?
|
| Stavudine | 3 | 2013 | 78 | 0.570 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 156 | 0.570 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2022 | 6 | 0.550 |
Why?
|
| Carotid Intima-Media Thickness | 5 | 2021 | 108 | 0.550 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 468 | 0.540 |
Why?
|
| Fatty Liver | 1 | 2016 | 8 | 0.530 |
Why?
|
| Child, Preschool | 14 | 2024 | 1748 | 0.520 |
Why?
|
| Azetidines | 3 | 2014 | 3 | 0.510 |
Why?
|
| Lipoproteins | 4 | 2024 | 13 | 0.510 |
Why?
|
| Diet | 4 | 2015 | 109 | 0.510 |
Why?
|
| Injections, Subcutaneous | 5 | 2020 | 22 | 0.500 |
Why?
|
| Oxazolidinones | 1 | 2015 | 4 | 0.490 |
Why?
|
| Lipoproteins, LDL | 5 | 2017 | 9 | 0.480 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 39 | 0.480 |
Why?
|
| Weight Loss | 1 | 2014 | 12 | 0.480 |
Why?
|
| Metabolic Syndrome | 4 | 2009 | 64 | 0.470 |
Why?
|
| Cohort Studies | 7 | 2024 | 967 | 0.450 |
Why?
|
| Animals | 7 | 2024 | 1081 | 0.440 |
Why?
|
| International Cooperation | 4 | 2018 | 50 | 0.440 |
Why?
|
| Blood Glucose | 14 | 2024 | 107 | 0.440 |
Why?
|
| Anti-HIV Agents | 5 | 2024 | 1324 | 0.430 |
Why?
|
| Guideline Adherence | 5 | 2019 | 43 | 0.430 |
Why?
|
| Body Mass Index | 8 | 2025 | 321 | 0.400 |
Why?
|
| Case-Control Studies | 7 | 2022 | 480 | 0.390 |
Why?
|
| Carotid Arteries | 3 | 2009 | 19 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 244 | 0.380 |
Why?
|
| Insulin | 9 | 2010 | 73 | 0.380 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2019 | 472 | 0.370 |
Why?
|
| Vitamin E | 4 | 2001 | 9 | 0.330 |
Why?
|
| Mass Screening | 2 | 2024 | 245 | 0.330 |
Why?
|
| Patient Safety | 2 | 2019 | 9 | 0.330 |
Why?
|
| DNA Mutational Analysis | 8 | 2019 | 34 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 262 | 0.320 |
Why?
|
| Cushing Syndrome | 2 | 2020 | 3 | 0.320 |
Why?
|
| Work Schedule Tolerance | 1 | 2008 | 2 | 0.310 |
Why?
|
| Cardiovascular System | 1 | 2008 | 3 | 0.310 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 5 | 0.310 |
Why?
|
| Signal Transduction | 1 | 2008 | 33 | 0.300 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 112 | 0.300 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 31 | 0.300 |
Why?
|
| Stroke | 4 | 2023 | 62 | 0.300 |
Why?
|
| Pilot Projects | 3 | 2020 | 179 | 0.300 |
Why?
|
| Occupational Diseases | 1 | 2008 | 40 | 0.290 |
Why?
|
| Pregnancy | 4 | 2023 | 1862 | 0.290 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 10 | 0.290 |
Why?
|
| Prospective Studies | 8 | 2019 | 1160 | 0.280 |
Why?
|
| Safety | 2 | 2018 | 34 | 0.280 |
Why?
|
| Fatty Acids | 3 | 2015 | 12 | 0.280 |
Why?
|
| Lymphocytes | 2 | 2017 | 20 | 0.280 |
Why?
|
| Cognition | 2 | 2024 | 75 | 0.270 |
Why?
|
| India | 3 | 2021 | 62 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 188 | 0.260 |
Why?
|
| Subtilisins | 2 | 2022 | 2 | 0.260 |
Why?
|
| Heredity | 3 | 2020 | 6 | 0.250 |
Why?
|
| Liver | 3 | 2016 | 74 | 0.250 |
Why?
|
| Standard of Care | 2 | 2023 | 30 | 0.250 |
Why?
|
| Consensus | 7 | 2020 | 62 | 0.250 |
Why?
|
| Africa | 4 | 2021 | 376 | 0.250 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 435 | 0.240 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2024 | 1 | 0.240 |
Why?
|
| Lipodystrophy | 2 | 2001 | 7 | 0.240 |
Why?
|
| DNA | 4 | 2017 | 73 | 0.240 |
Why?
|
| Clinical Studies as Topic | 1 | 2024 | 2 | 0.230 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 370 | 0.230 |
Why?
|
| Overweight | 1 | 2025 | 87 | 0.230 |
Why?
|
| Sulfonic Acids | 1 | 2003 | 3 | 0.230 |
Why?
|
| Microcirculation | 1 | 2023 | 5 | 0.230 |
Why?
|
| Acetates | 1 | 2003 | 7 | 0.230 |
Why?
|
| Patients | 1 | 2023 | 3 | 0.220 |
Why?
|
| Adiponectin | 3 | 2012 | 15 | 0.220 |
Why?
|
| Dietary Proteins | 2 | 1994 | 4 | 0.220 |
Why?
|
| Phosphates | 1 | 2023 | 10 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2014 | 19 | 0.220 |
Why?
|
| Lovastatin | 3 | 2017 | 4 | 0.210 |
Why?
|
| Epidemiologic Studies | 1 | 2022 | 13 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2022 | 5 | 0.210 |
Why?
|
| Alleles | 4 | 2020 | 143 | 0.210 |
Why?
|
| Pedigree | 7 | 2019 | 30 | 0.210 |
Why?
|
| Antigen-Antibody Complex | 1 | 2022 | 11 | 0.210 |
Why?
|
| Disease Progression | 3 | 2012 | 154 | 0.210 |
Why?
|
| Phospholipids | 1 | 2022 | 13 | 0.210 |
Why?
|
| Glucose | 3 | 2018 | 45 | 0.210 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 77 | 0.200 |
Why?
|
| Dietary Carbohydrates | 2 | 2012 | 4 | 0.200 |
Why?
|
| Dietary Fats | 2 | 2012 | 7 | 0.200 |
Why?
|
| Adenine | 2 | 2013 | 91 | 0.200 |
Why?
|
| Apolipoproteins E | 2 | 2021 | 4 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.200 |
Why?
|
| Research Design | 2 | 2016 | 124 | 0.200 |
Why?
|
| Linear Models | 6 | 2013 | 83 | 0.200 |
Why?
|
| Sodium | 1 | 2022 | 30 | 0.200 |
Why?
|
| Risk | 2 | 2019 | 87 | 0.200 |
Why?
|
| Rosuvastatin Calcium | 3 | 2017 | 3 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2022 | 111 | 0.200 |
Why?
|
| Genetic Counseling | 2 | 2019 | 14 | 0.200 |
Why?
|
| Arthralgia | 1 | 2021 | 4 | 0.200 |
Why?
|
| Skin Diseases | 1 | 2021 | 6 | 0.190 |
Why?
|
| Nucleic Acids | 1 | 2021 | 7 | 0.190 |
Why?
|
| Apolipoprotein E2 | 1 | 2021 | 3 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2019 | 149 | 0.190 |
Why?
|
| Xanthomatosis, Cerebrotendinous | 1 | 2021 | 1 | 0.190 |
Why?
|
| Skin | 1 | 2021 | 38 | 0.190 |
Why?
|
| Point Mutation | 2 | 1998 | 16 | 0.180 |
Why?
|
| Drug Interactions | 2 | 2022 | 31 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 44 | 0.180 |
Why?
|
| Disease Management | 2 | 2019 | 74 | 0.180 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 5 | 0.180 |
Why?
|
| Primary Prevention | 1 | 2020 | 27 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 16 | 0.180 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.180 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 55 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 4 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 13 | 0.180 |
Why?
|
| Influenza, Human | 1 | 2024 | 374 | 0.170 |
Why?
|
| Program Evaluation | 1 | 2020 | 89 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 7 | 0.170 |
Why?
|
| Health Status | 1 | 2021 | 111 | 0.170 |
Why?
|
| Global Health | 2 | 2018 | 193 | 0.170 |
Why?
|
| Submandibular Gland | 1 | 2019 | 2 | 0.170 |
Why?
|
| Homeostasis | 2 | 2018 | 9 | 0.170 |
Why?
|
| Comorbidity | 1 | 2020 | 188 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2019 | 10 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 61 | 0.170 |
Why?
|
| Hyperinsulinism | 1 | 1999 | 4 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 6 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 16 | 0.160 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2015 | 2 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2018 | 9 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 71 | 0.160 |
Why?
|
| Cataract | 1 | 2018 | 2 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 8 | 0.160 |
Why?
|
| Health Care Surveys | 3 | 2018 | 30 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 12 | 0.150 |
Why?
|
| Albuminuria | 3 | 2010 | 20 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2018 | 38 | 0.150 |
Why?
|
| Calcinosis | 1 | 2018 | 11 | 0.150 |
Why?
|
| Urban Population | 7 | 2010 | 257 | 0.150 |
Why?
|
| Cognition Disorders | 1 | 2018 | 36 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 106 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 117 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2017 | 9 | 0.150 |
Why?
|
| Xanthomatosis | 2 | 2014 | 2 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2018 | 120 | 0.150 |
Why?
|
| Infant | 3 | 2024 | 2244 | 0.150 |
Why?
|
| Apolipoprotein A-I | 1 | 2017 | 3 | 0.140 |
Why?
|
| Europe | 4 | 2019 | 56 | 0.140 |
Why?
|
| Internationality | 2 | 2015 | 36 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2017 | 55 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 253 | 0.140 |
Why?
|
| Sex Factors | 3 | 2023 | 227 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 303 | 0.140 |
Why?
|
| Professional Practice Gaps | 1 | 2016 | 2 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2016 | 8 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 1996 | 1 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 33 | 0.130 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2015 | 167 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 22 | 0.130 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2015 | 1 | 0.130 |
Why?
|
| Dicarboxylic Acids | 1 | 2015 | 1 | 0.130 |
Why?
|
| PPAR delta | 1 | 2015 | 1 | 0.130 |
Why?
|
| American Heart Association | 1 | 2015 | 1 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2007 | 10 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2015 | 23 | 0.130 |
Why?
|
| Tunica Intima | 2 | 2009 | 6 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2015 | 5 | 0.130 |
Why?
|
| Hypertriglyceridemia | 2 | 2013 | 3 | 0.130 |
Why?
|
| Oxidation-Reduction | 4 | 2022 | 24 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2015 | 1 | 0.120 |
Why?
|
| Leptin | 2 | 2009 | 26 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 1994 | 1 | 0.120 |
Why?
|
| Antioxidants | 1 | 1994 | 26 | 0.120 |
Why?
|
| Ultracentrifugation | 1 | 2014 | 1 | 0.110 |
Why?
|
| Medication Adherence | 2 | 2015 | 151 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 3 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 2 | 0.110 |
Why?
|
| Multifactorial Inheritance | 1 | 2013 | 9 | 0.110 |
Why?
|
| Patient Care | 1 | 2013 | 10 | 0.110 |
Why?
|
| Apoptosis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2014 | 62 | 0.110 |
Why?
|
| Phosphorous Acids | 1 | 2013 | 14 | 0.110 |
Why?
|
| Glucose Clamp Technique | 2 | 2010 | 4 | 0.110 |
Why?
|
| Haplotypes | 5 | 2006 | 125 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2024 | 43 | 0.110 |
Why?
|
| Societies, Medical | 3 | 2019 | 26 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 34 | 0.110 |
Why?
|
| Cooperative Behavior | 3 | 2018 | 17 | 0.100 |
Why?
|
| Adipocytes | 1 | 2012 | 23 | 0.100 |
Why?
|
| Endothelium, Vascular | 2 | 2021 | 29 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 45 | 0.100 |
Why?
|
| Postprandial Period | 2 | 2009 | 4 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 353 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 4 | 2000 | 11 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 118 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2012 | 27 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2011 | 10 | 0.100 |
Why?
|
| Awareness | 1 | 2011 | 18 | 0.100 |
Why?
|
| Perception | 1 | 2011 | 42 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 48 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 133 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 20 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 96 | 0.090 |
Why?
|
| Genotype | 4 | 2020 | 442 | 0.090 |
Why?
|
| Logistic Models | 1 | 2011 | 254 | 0.090 |
Why?
|
| Proteins | 2 | 2001 | 20 | 0.090 |
Why?
|
| Pandemics | 2 | 2024 | 296 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 106 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 23 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2015 | 56 | 0.090 |
Why?
|
| Urban Health | 3 | 2019 | 78 | 0.090 |
Why?
|
| Allylamine | 1 | 2009 | 1 | 0.090 |
Why?
|
| Sequence Deletion | 2 | 2001 | 16 | 0.090 |
Why?
|
| Early Diagnosis | 3 | 2015 | 82 | 0.080 |
Why?
|
| Tunica Media | 1 | 2009 | 3 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2003 | 127 | 0.080 |
Why?
|
| Founder Effect | 2 | 2001 | 16 | 0.080 |
Why?
|
| Lipoproteins, VLDL | 1 | 2009 | 1 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 563 | 0.080 |
Why?
|
| Waist Circumference | 2 | 2025 | 60 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2020 | 13 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2009 | 15 | 0.080 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2008 | 1 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 1998 | 260 | 0.080 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 5 | 0.080 |
Why?
|
| Inflammation Mediators | 2 | 2009 | 22 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 12 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2008 | 49 | 0.070 |
Why?
|
| Fluorobenzenes | 1 | 2007 | 1 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 685 | 0.070 |
Why?
|
| Diabetes Mellitus, Lipoatrophic | 2 | 1997 | 2 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2022 | 20 | 0.070 |
Why?
|
| Africa, Southern | 1 | 2007 | 91 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 25 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2007 | 32 | 0.070 |
Why?
|
| Middle East | 2 | 2019 | 8 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2017 | 79 | 0.070 |
Why?
|
| E-Selectin | 3 | 2004 | 14 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 187 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2004 | 20 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2004 | 25 | 0.070 |
Why?
|
| Exercise | 1 | 2009 | 205 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2017 | 31 | 0.070 |
Why?
|
| Reference Values | 2 | 2003 | 64 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2005 | 11 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2025 | 29 | 0.060 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2024 | 1 | 0.060 |
Why?
|
| Birds | 1 | 2024 | 2 | 0.060 |
Why?
|
| Influenza in Birds | 1 | 2024 | 3 | 0.060 |
Why?
|
| Glucose Tolerance Test | 4 | 2010 | 33 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2005 | 91 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 16 | 0.060 |
Why?
|
| Acetamides | 1 | 2003 | 1 | 0.060 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2003 | 1 | 0.060 |
Why?
|
| Lipoproteins, HDL | 1 | 2003 | 9 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2003 | 20 | 0.060 |
Why?
|
| Probability | 1 | 2003 | 27 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 22 | 0.060 |
Why?
|
| Phytosterols | 1 | 2003 | 1 | 0.060 |
Why?
|
| Iron Overload | 1 | 2003 | 1 | 0.060 |
Why?
|
| Iron, Dietary | 1 | 2003 | 2 | 0.060 |
Why?
|
| Hormones | 1 | 2003 | 9 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2017 | 25 | 0.050 |
Why?
|
| Food, Fortified | 1 | 2003 | 11 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 198 | 0.050 |
Why?
|
| Iron | 1 | 2003 | 32 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 171 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2023 | 14 | 0.050 |
Why?
|
| DNA, Mitochondrial | 2 | 2013 | 31 | 0.050 |
Why?
|
| Malondialdehyde | 1 | 2022 | 3 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 24 | 0.050 |
Why?
|
| Headache | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cause of Death | 1 | 2004 | 221 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 3 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2023 | 42 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 22 | 0.050 |
Why?
|
| Inflammation | 2 | 2013 | 104 | 0.050 |
Why?
|
| Self Report | 1 | 2022 | 114 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 73 | 0.050 |
Why?
|
| Epitopes | 1 | 2022 | 97 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ritonavir | 1 | 2022 | 137 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 253 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 42 | 0.050 |
Why?
|
| Transcriptome | 1 | 2021 | 14 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2001 | 1 | 0.050 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2001 | 1 | 0.050 |
Why?
|
| Jews | 1 | 2001 | 1 | 0.050 |
Why?
|
| Receptors, Lipoprotein | 1 | 2001 | 1 | 0.050 |
Why?
|
| Syndrome | 1 | 2001 | 19 | 0.050 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2021 | 1 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2001 | 7 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2001 | 5 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 124 | 0.050 |
Why?
|
| Apolipoproteins A | 2 | 2000 | 2 | 0.050 |
Why?
|
| Burkina Faso | 1 | 2021 | 29 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2001 | 36 | 0.050 |
Why?
|
| Ghana | 1 | 2021 | 67 | 0.050 |
Why?
|
| Exons | 2 | 1998 | 17 | 0.050 |
Why?
|
| Mice | 1 | 2001 | 135 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2021 | 77 | 0.040 |
Why?
|
| Mevalonic Acid | 1 | 2000 | 1 | 0.040 |
Why?
|
| Kenya | 1 | 2021 | 183 | 0.040 |
Why?
|
| Skin Lightening Preparations | 1 | 2020 | 2 | 0.040 |
Why?
|
| Azathioprine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 3 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2015 | 133 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 7 | 0.040 |
Why?
|
| Graves Disease | 1 | 2000 | 1 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2020 | 11 | 0.040 |
Why?
|
| Microsomes | 1 | 2019 | 4 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2000 | 49 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2019 | 5 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 199 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.040 |
Why?
|
| Dinoprost | 1 | 1999 | 2 | 0.040 |
Why?
|
| F2-Isoprostanes | 1 | 1999 | 2 | 0.040 |
Why?
|
| Genetic Heterogeneity | 2 | 2014 | 9 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 77 | 0.040 |
Why?
|
| Weight Gain | 1 | 2019 | 77 | 0.040 |
Why?
|
| North America | 1 | 2018 | 11 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 122 | 0.040 |
Why?
|
| Fasting | 2 | 2009 | 16 | 0.040 |
Why?
|
| Income | 1 | 2019 | 85 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 72 | 0.040 |
Why?
|
| Algorithms | 2 | 2010 | 106 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 118 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 43 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 1997 | 10 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2017 | 2 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 25 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2020 | 240 | 0.040 |
Why?
|
| Cyprus | 1 | 1997 | 1 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 5 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 656 | 0.040 |
Why?
|
| Bezafibrate | 1 | 1997 | 2 | 0.040 |
Why?
|
| Immunoblotting | 1 | 1997 | 2 | 0.040 |
Why?
|
| Cats | 1 | 1997 | 3 | 0.040 |
Why?
|
| Sodium Fluoride | 1 | 1997 | 2 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2016 | 6 | 0.030 |
Why?
|
| Access to Information | 1 | 2016 | 2 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 13 | 0.030 |
Why?
|
| Data Mining | 1 | 2016 | 8 | 0.030 |
Why?
|
| Osteoporosis | 1 | 1997 | 14 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1997 | 38 | 0.030 |
Why?
|
| Medical Audit | 1 | 1996 | 26 | 0.030 |
Why?
|
| Photography | 1 | 1996 | 5 | 0.030 |
Why?
|
| Vision Screening | 1 | 1996 | 3 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 1996 | 5 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 280 | 0.030 |
Why?
|
| Receptor, Insulin | 2 | 1992 | 4 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 2 | 0.030 |
Why?
|
| United States | 1 | 2015 | 132 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1995 | 12 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 21 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 2 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 2015 | 3 | 0.030 |
Why?
|
| Rural Population | 2 | 1997 | 654 | 0.030 |
Why?
|
| Mitochondria, Muscle | 1 | 2015 | 2 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1995 | 46 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 3 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 40 | 0.030 |
Why?
|
| Urea | 1 | 1994 | 3 | 0.030 |
Why?
|
| Proteinuria | 1 | 1994 | 14 | 0.030 |
Why?
|
| Arcus Senilis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Lipid Peroxides | 1 | 1994 | 6 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 63 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 38 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 54 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 1994 | 62 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 57 | 0.030 |
Why?
|
| Counseling | 1 | 2015 | 143 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2014 | 55 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 40 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 20 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Age of Onset | 1 | 1993 | 32 | 0.030 |
Why?
|
| Alkynes | 1 | 2013 | 117 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1993 | 89 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2013 | 123 | 0.030 |
Why?
|
| Lamivudine | 1 | 2013 | 89 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 102 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 1479 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2013 | 123 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 41 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.030 |
Why?
|
| Health Promotion | 1 | 2013 | 109 | 0.030 |
Why?
|
| Supine Position | 1 | 1992 | 5 | 0.030 |
Why?
|
| Diet Surveys | 1 | 1992 | 7 | 0.030 |
Why?
|
| African Americans | 1 | 1992 | 47 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 153 | 0.020 |
Why?
|
| Thyrotropin | 2 | 2003 | 5 | 0.020 |
Why?
|
| Monocytes | 1 | 1992 | 27 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 27 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 100 | 0.020 |
Why?
|
| Tenofovir | 1 | 2012 | 171 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1992 | 120 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 239 | 0.020 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2010 | 1 | 0.020 |
Why?
|
| Mitosporic Fungi | 1 | 1989 | 1 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2009 | 1 | 0.020 |
Why?
|
| Brain Abscess | 1 | 1989 | 3 | 0.020 |
Why?
|
| Mycoses | 1 | 1989 | 8 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 385 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 34 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1988 | 11 | 0.020 |
Why?
|
| Platelet Count | 1 | 1988 | 14 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1988 | 15 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1988 | 24 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 1988 | 29 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1988 | 65 | 0.020 |
Why?
|
| C-Peptide | 2 | 2002 | 13 | 0.020 |
Why?
|
| Base Sequence | 2 | 1998 | 149 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 107 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2006 | 14 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1997 | 11 | 0.020 |
Why?
|
| Vasodilation | 1 | 2004 | 7 | 0.010 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2003 | 2 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2003 | 2 | 0.010 |
Why?
|
| Prolactin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2003 | 5 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2003 | 11 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2003 | 10 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 14 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 18 | 0.010 |
Why?
|
| Copper | 1 | 2001 | 15 | 0.010 |
Why?
|
| Quality Control | 1 | 2001 | 27 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 77 | 0.010 |
Why?
|
| Particle Size | 1 | 2001 | 73 | 0.010 |
Why?
|
| Acanthosis Nigricans | 1 | 2001 | 1 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Hepatomegaly | 1 | 2001 | 1 | 0.010 |
Why?
|
| Lebanon | 1 | 2001 | 1 | 0.010 |
Why?
|
| Hyperandrogenism | 1 | 2001 | 1 | 0.010 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 1 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2001 | 5 | 0.010 |
Why?
|
| Norway | 1 | 2001 | 2 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 8 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 10 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2001 | 11 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 27 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 22 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 15 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2001 | 65 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2001 | 1 | 0.010 |
Why?
|
| CD36 Antigens | 1 | 2001 | 1 | 0.010 |
Why?
|
| Penetrance | 1 | 2001 | 1 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2001 | 1 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2001 | 1 | 0.010 |
Why?
|
| Lithuania | 1 | 2001 | 2 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 13 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2001 | 40 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 263 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 99 | 0.010 |
Why?
|
| Thyroxine | 1 | 2000 | 1 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 5 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 1998 | 3 | 0.010 |
Why?
|
| Germany | 1 | 1998 | 6 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 8 | 0.010 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1997 | 1 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1998 | 35 | 0.010 |
Why?
|
| Codon | 1 | 1997 | 7 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 1997 | 1 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 1997 | 2 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1997 | 68 | 0.010 |
Why?
|
| Creatinine | 1 | 1995 | 53 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1994 | 8 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1994 | 107 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1993 | 31 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1992 | 3 | 0.010 |
Why?
|
| Urbanization | 1 | 1992 | 11 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 25 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1993 | 411 | 0.010 |
Why?
|
| Brain | 1 | 1989 | 53 | 0.010 |
Why?
|